Drug Trial Radar · NCT01309243
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Last checked: Nov 20, 2026Latest source record: Feb 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
799
Actual
Start
Feb 2011
Primary completion
Sep 2012
Study completion Feb 2014
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or \> 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.
Conditions
- HIV-1 Infection
Interventions
FTC/RPV/TDFDrug
Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
EFV/FTC/TDFDrug
Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48
Locations
151 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Spectrum Medical Group
Phoenix, Arizona
AHF Research Center
Beverly Hills, California
Kaiser Permanente Medical Center
Hayward, California
Living Hope Education and Research Consultants
Long Beach, California
Kaiser Permanente Medical Center
Los Angeles, California
Jeffrey Goodman Special Care Clinic/Los Angeles Gay and Lesbian Center
Los Angeles, California
Lightsource Medical
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Oasis Clinic
Los Angeles, California
Anthony Mills MD Inc
Los Angeles, California
Orange Coast Medical Group
Newport Beach, California
East Bay AIDS Center
Oakland, California
Stanford University
Palo Alto, California
University of California, Davis
Sacramento, California
Kaiser Permanente Medical Group
Sacramento, California
La Playa Medical Group and Clinical Research
San Diego, California
Metropolis Medical/Dr.Fritz
San Francisco, California
Kaiser Permanente Medical Center, San Francisco
San Francisco, California
Apex Research LLC
Denver, Colorado
Dupont Circle Physician's Group
Washington D.C., District of Columbia
Whitman-Walker Clinic
Washington D.C., District of Columbia
Capital Medical Associates, PC
Washington D.C., District of Columbia
Medical Faculty Associates
Washington D.C., District of Columbia
Broward General Medical Center
Fort Lauderdale, Florida
Gary J. Richmond, M.D., P.A.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
The Kinder Medical Group
Miami, Florida
Wohlfeiler, Piperato and Associates, LLC
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
Valuhealthmd,Llc / Idocf
Orlando, Florida
Infectious Disease Associates of NW FL
Pensacola, Florida
AHF Health Positive - Tampa Bay
Safety Harbor, Florida
St. Joseph's Hospital d/b/a Comprehensive Research Institute
Tampa, Florida
Emory University
Atlanta, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Atlanta ID Group
Atlanta, Georgia
Infectious Disease Specialists of America
Decatur, Georgia
Mercer University School of Medicine
Macon, Georgia
Clint Spencer Clinic
Honolulu, Hawaii
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.